Draupnir Bio ApS
Core data
Name | Draupnir Bio ApS |
Address | Nordre Fasanvej 215, 2000, Frederiksberg |
Founded | Apr 4, 2017 |
Employees (CVR) | 13 |
Locations (P-units) | 2View locations |
Website | https://draupnir.bio/ |
 LinkedIn | draupnirbio |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Name | Draupnir Bio ApS |
Address | Nordre Fasanvej 215, 2000, Frederiksberg |
Founded | Apr 4, 2017 |
Employees (CVR) | 13 |
Locations (P-units) | 2View locations |
Website | https://draupnir.bio/ |
| LinkedIn | draupnirbio |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Keep track of Draupnir Bio ApS
Description
Draupnir Bio is a biotechnology spin-out company developing extracellular targeted protein degradation technologies and therapies using sortilin-based lysosome targeting chimeras (SORTACs). The company is based in Copenhagen, with research operations in Aarhus, Denmark.
Draupnir Bio develops oral small-molecule degraders and other multimodality approaches that harness lysosome receptors to target extracellular and membrane-bound proteins, including protein aggregates, for therapeutic applications.
Products & services
SORTACs (SORtilin-based lysosome TArgeting Chimeras) · Oral small-molecule degraders of extracellular pathogenic proteins · Targeted extracellular protein degradation platform · Preclinical pipeline against protein aggregates
Industries
Biotechnology · Drug development · Targeted protein degradation
Customer types
Patients with diseases involving pathogenic protein aggregates
Financials
| Reporting period | 2025DKK | ||||||
|---|---|---|---|---|---|---|---|
| Revenue | 45,120,000 | ||||||
| Profit before tax | -14,198,000 | ||||||
| Net income | -12,310,000 | ||||||
| Total assets | 39,072,000 | ||||||
| Equity | 15,256,000 | ||||||
2017–2025 Unlock financial history | |||||||
Datapublica Risk Score
What goes into the assessment
Financials
Equity ratio, profitability, and liquidity
Accounts and history
Late filings and previous financial distress
Owners and management
Past bankruptcies and owners’ other companies
Company and connections
Age, industry, and shared addresses or contact details
Standard: Score and risk bandPro: Also a detailed explanation of the factors
Contact
From draupnir.bio
| Contact | Phone | |
|---|---|---|
| Main | — | in**@draupnir.bioShow full |
Gazelle
Loading gazelle status…
Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.
People
| Person | Roles | Titles |
|---|---|---|
| Emmanuelle Coutanceau | Roles Board | TitlesBESTYRELSESMEDLEM |
| Simon Glerup Pedersen | Roles Board | TitlesBESTYRELSESMEDLEM |
Auditor
| Audit firm | Auditor | Role | From |
|---|---|---|---|
| Deloitte Statsautoriseret Revisionspartnerselskab | AuditorJens Serup | RoleState-Authorised Public Accountant | FromJun 4, 2026 |
Legal owners
| Owner | Ownership | Voting rights | From |
|---|---|---|---|
Unknown Other Participant | Ownership20–24.99 % | Voting rights20 % | FromJul 10, 2024 |
Unknown Other Participant | Ownership20–24.99 % | Voting rights20 % | FromJun 29, 2026 |
| Ownership20–24.99 % | Voting rights20 % | FromJul 10, 2024 | |
| Ownership10–14.99 % | Voting rights10 % | FromJul 10, 2024 | |
Foreign legal entity | Ownership10–14.99 % | Voting rights10 % | FromMar 26, 2024 |
Ultimate owners
| Name | Ownership through | Calculated ownership |
|---|---|---|
| 🇳🇱Coöperatieve Gilde Healthcare IV U.A. | Ownership through Direct | 20–24.99 % |
| 🇳🇱INKEF Holding Coöperatief U.A. | Ownership through Direct | 20–24.99 % |
| NOVO NORDISK FONDEN | Ownership through | 20–24.99 % |
| Danmarks Eksport- og Investeringsfond | Ownership through Direct | 10–14.99 % |
| 🇺🇸MP Healthcare Venture Management, Inc, | Ownership through Direct | 10–14.99 % |